Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 The Dohmen ... Floyd , Ph.D., MBA as Chief Science Officer ... this newly created role, Dr. Floyd will lead ... a portfolio of pre-commercial and post approval outsourced ... and medical communications.  Dr. Floyd brings decades of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Director of Business Development, Asia Pacific. In this newly-created position, Gibbs will lead ... and use of iLab’s suite of tools. This entails not only introducing iLab ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... Board of Directors as a Non-Executive Director. Sara will also ... of the Shire Board. Both appointments will be effective as ... Chairman, President and Chief Executive Officer of Dun & Bradstreet, ... at D&B, she helped drive the transformation of the company ...
(Date:8/31/2015)... Aug. 31, 2015 MabVax Therapeutics Holdings, Inc. ... that the Company,s lead antibody, HuMab 5B1, will be ... presentations during the upcoming World Molecular Imaging Congress (WMIC) ... 2-5, 2015. Researchers from the Department of Radiology at ... on the use of MabVax,s lead antibody as a ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... ... Scientists to Deliver Results Faster with New User Interface and Improved Support for Complex ... (PRWEB) ... discovery and life science research, today announced Genedata Screener® 8. Developed over the past ...
... single-atom thick material graphene maintains its high thermal conductivity ... advancing the material from a laboratory phenomenon to a ... report in the April 9 issue of the journal ... theoretical physicists from the University of Texas at Austin, ...
... of Mechanical Engineering at Stevens Institute of Technology was ... Program (YIP) award by the Office of Naval Research ... show exceptional promise for creative study. "We are ... engineers," said ONR,s Director of Research Dr. Michael Kassner. ...
Cached Biology Technology:Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 2Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 3Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference 4With support, graphene still a superior thermal conductor 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 3
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... (15 February 2013)Scientists at the Nairobi-based World Agroforestry Centre ... out fire behavior, known as nomographs, for landscape managers ... issue of the Journal of Arid Environments , ... process that when executed and timed properly, reduces the ...
... of molecular biology is how the interactions of proteins ... the mid-20th century discoveries of the lac repressor and ... proteins for the same segment of DNA, we have ... with DNA and their control of fundamental processes in ...
... cells with energy, to nitrogen fixation, to the splitting ... proteins that contain a metal ion are vital ... chemistry behind these catalytic activities could pave the way ... that would provide clean, green and renewable energy. ...
Cached Biology News:Scientists develop improved fire management tools for Africa's savannas 2Scientists develop improved fire management tools for Africa's savannas 3A dual look at photosystem II using the world's most powerful X-ray laser 2A dual look at photosystem II using the world's most powerful X-ray laser 3
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... Chamber lid allows easy gel observation and provides ... easy set up between power supply and migration ... if the lid is removed at the migration ... Remote control can be easily operated in ...
... have low background fluorescence, minimal light ... (or medium binding) polystyrene surface is ... through passive interactions,• Is suitable ... molecules, such as antibodies, that have ...
... Model 1575 immunowash microplate washer 100-240 V, ... have flat-, U-, or V-bottom wells. The ... and vertical needle positions to an accuracy ... aspiration, and overflow washing. It can store ...
Biology Products: